Merck (MRK) Wins FDA Approval For First Oral PCSK9 Cholesterol Drug

Merck (MRK) has received FDA approval for Lipfendra (enlicitide), the first oral PCSK9 cholesterol-lowering drug, marking a significant expansion of its cardiovascular medicine portfolio. This approval introduces an oral alternative to existing injectable PCSK9 therapies, strengthening Merck's market position as key product patents approach expiration. The company has demonstrated strong stock performance, with a 64.8% return over the past year and 92.2% over five years.